Lipocine Inc Total Assets
Lipocine Inc total assets. Based on the latest financial reports, Lipocine Inc (LPCN) holds total assets worth $23.84 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Lipocine Inc (LPCN) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Lipocine Inc (2011–2025)
Total assets of Lipocine Inc from 2011 to 2025. This chart illustrates how Lipocine Inc's total assets have evolved over time, based on quarterly financial data. See today's stock price for Lipocine Inc for real-time trading data and today's change.
Lipocine Inc - Asset Composition Analysis
Lipocine Inc Total Assets Breakdown (December 2025)
Lipocine Inc total assets breakdown as of December 2025. Lipocine Inc's total assets of $23.84 Million consist of 99.3% current assets and 0.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 30.6% |
| Accounts Receivable | $14.19K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Lipocine Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Lipocine Inc current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lipocine Inc's current assets represent 99.3% of total assets in 2025, a decrease from 100.0% in 2011.
- Cash Position: Cash and equivalents constituted 30.6% of total assets in 2025, down from 70.7% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
Lipocine Inc Competitors by Total Assets
Key competitors of Lipocine Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Lipocine Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.48 | 12.71 | 6.28 |
| Quick Ratio | 11.48 | 12.71 | 6.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $21.67 Million | $16.97 Million | $33.93 Million |
Lipocine Inc - Advanced Valuation Insights
This section examines the relationship between Lipocine Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.89 |
| Latest Market Cap to Assets Ratio | 0.71 |
| Asset Growth Rate (YoY) | -24.5% |
| Total Assets | $17.01 Million |
| Market Capitalization | $12.04 Million USD |
Valuation Analysis
Below Book Valuation: The market values Lipocine Inc's assets below their book value (0.71x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Lipocine Inc's assets decreased by 24.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lipocine Inc (2011–2025)
The table below shows the annual total assets of Lipocine Inc from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $17.01 Million | -24.45% |
| 2024-12-31 | $22.51 Million | -2.13% |
| 2023-12-31 | $23.00 Million | -38.73% |
| 2022-12-31 | $37.54 Million | -28.47% |
| 2021-12-31 | $52.48 Million | +107.01% |
| 2020-12-31 | $25.35 Million | +28.97% |
| 2019-12-31 | $19.66 Million | -5.72% |
| 2018-12-31 | $20.85 Million | -17.66% |
| 2017-12-31 | $25.33 Million | -7.38% |
| 2016-12-31 | $27.34 Million | -39.74% |
| 2015-12-31 | $45.38 Million | +62.10% |
| 2014-12-31 | $27.99 Million | -39.29% |
| 2013-12-31 | $46.11 Million | +7990805.03% |
| 2012-12-31 | $577.00 | -98.22% |
| 2011-12-31 | $32.44K | -- |
About Lipocine Inc
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1… Read more